Factorial Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Factorial Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-232,000	Closed	-$6.99M	–	48
2026 Q1	$6.99M	Sell	232,000 -58,000	-20%	-$1.87M	5.07%	3
2025 Q4	$9.05M	Sell	290,000 -55,000	-16%	-$1.35M	5.98%	1
2025 Q3	$6.97M	Hold	345,000	–	–	4.8%	3
2025 Q2	$5.78M	Buy	345,000 +12,000	+4%	+$194K	4.19%	4
2025 Q1	$5.12M	Buy	333,000 +1,000	+0.3%	+$17.9K	3.16%	6
2024 Q4	$7.32M	Buy	332,000 +21,000	+7%	+$382K	4.2%	1
2024 Q3	$5.6M	Buy	311,000 +39,000	+14%	+$683K	3.23%	3
2024 Q2	$4.42M	Hold	272,000	–	–	2.72%	6
2024 Q1	$3.84M	Buy	272,000 +29,000	+12%	+$366K	2.18%	9
2023 Q4	$2.54M	Buy	243,000 +13,000	+6%	+$121K	1.61%	24
2023 Q3	$2.35M	Buy	230,000 +27,500	+14%	+$256K	1.71%	21
2023 Q2	$1.52M	Buy	202,500 +48,000	+31%	+$389K	1.05%	35
2023 Q1	$1.37M	Sell	154,500 -22,000	-12%	-$218K	1.03%	35
2022 Q4	$1.61M	Buy	176,500 +3,500	+2%	+$30.5K	1.23%	32
2022 Q3	$1.4M	Buy	173,000 +28,500	+20%	+$252K	1.21%	29
2022 Q2	$1.09M	Sell	144,500 -6,500	-4%	-$56.6K	0.88%	45
2022 Q1	$1.42M	Buy	151,000 +63,000	+72%	+$526K	0.97%	44
2021 Q4	$705K	Sell	88,000 -67,000	-43%	-$605K	0.47%	70
2021 Q3	$1.51M	Hold	155,000	–	–	1.03%	36
2021 Q2	$1.53M	Hold	155,000	–	–	1.04%	38
2021 Q1	$1.79M	Hold	155,000	–	–	1.26%	27
2020 Q4	$1.5M	Hold	155,000	–	–	1.25%	26
2020 Q3	$1.4M	Buy	155,000 +2,000	+1%	+$21.2K	1.43%	21
2020 Q2	$1.89M	Hold	153,000	–	–	2.07%	12
2020 Q1	$1.37M	Sell	153,000 -3,000	-2%	-$30.7K	1.83%	17
2019 Q4	$1.53M	Hold	156,000	–	–	1.34%	19
2019 Q3	$1.07M	Hold	156,000	–	–	1.03%	27
2019 Q2	$1.44M	Buy	156,000 +1,000	+0.6%	+$12.1K	1.38%	22
2019 Q1	$2.43M	Buy	155,000 +6,000	+4%	+$106K	2.29%	8
2018 Q4	$2.3M	Hold	149,000	–	–	2.41%	9
2018 Q3	$3.21M	Sell	149,000 -4,000	-3%	-$92.9K	2.76%	5
2018 Q2	$3.72M	Hold	153,000	–	–	3.33%	2
2018 Q1	$2.61M	Buy	153,000 +6,000	+4%	+$117K	2.39%	9
2017 Q4	$2.79M	Buy	+147,000	New	+$2.21M	2.58%	8

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Factorial Partners's TEVA Position: Q2 2026 in Review

Factorial Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 232,000 shares — an estimated $6.99M sold.

Factorial Partners first reported a position in TEVA in Q4 2017 and held it in 34 quarters. The position peaked at $9.05M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Factorial Partners reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Factorial Partners sold 232,000 Teva Pharmaceuticals shares in Q2 2026, an estimated $6.99M.
Factorial Partners first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 34 quarters.
Factorial Partners's Teva Pharmaceuticals position peaked at $9.05M in Q4 2025.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Factorial Partners's 13F filing for Q2 2026, filed 14 Aug 2026.